Table of Contents
Ridgeback Biotherapeutics
Ridgeback Biotherapeutics is a biotechnology company based in Miami, Florida.1)
Ridgeback collaborated with Merck to develop molnupiravir, an oral mutagenic anti-viral compound, to treat COVID-19.2)
1)
Moody, M., Ryan, P., Dannenbaum, P., Kruper, R., & Carvalho, C. (2021, October 1). Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study. Merck. Retrieved December 5, 2021, from https://archive.ph/Ov4Cg
2)
Linnane, C. (2022, January 18). Merck and Ridgeback Biotherapeutics to supply 3 million doses of COVID antiviral to Unicef in 2022. MarketWatch. https://archive.ph/ZbutW